United Therapeutics | UTHR - Des Atouts





Des Atouts Changement Date
Amarin USD 645.76M 25.01M 2026-03
Ardelyx USD 504.51M 2.9M 2026-03
Baxter International USD 19.85B 209M 2026-03
Bayer EUR 104.54B 331M 2025-12
BioCryst Pharmaceuticals USD 514.16M 67.73M 2025-12
Biogen USD 29.48B 43.6M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Emergent BioSolutions USD 1.82B 69.9M 2023-12
Esperion Therapeutics USD 465.89M 101.87M 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
Halozyme Therapeutics USD 2.53B 304.09M 2025-12
Insmed USD 2.26B 96.18M 2025-12
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
J&J USD 200.89B 1.68B 2026-03
Lexicon Pharmaceuticals USD 184.99M 20.94M 2025-12
Moderna USD 11.49B 850M 2026-03
Omeros USD 200.57M 34.59M 2025-06
Pfizer USD 207.62B 542M 2026-03
PTC Therapeutics USD 2.9B 255.07M 2025-12
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
Teva Pharmaceutical Industries USD 40.04B 708M 2026-03
United Therapeutics USD 7.88B 528.9M 2025-12
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03